logo

For the Inventor, By the Inventor

Hightstown, NJ, United States of America

David Kenneth Leahy

This inventor holds 11 USPTO granted patents and 11 published patent applications, plus 1 CIPO patent. Top assignees: Bristol-Myers Squibb Compnay, Viiv Healthcare UK (No. 4) Limited. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David Kenneth Leahy. Retrieved from https://idiyas.com/inventor/david-kenneth-leahy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 

% Patents Active = 100.0


Average Co-Inventor Count = 9.6

ph-index = 4

Forward Citations = 59(Granted Patents)


Location History:

  • Morristown, NJ (US) (2010 - 2012)
  • Somerset, NJ (US) (2010 - 2022)
  • Hightstown, NJ (US) (2010 - 2022)

Company Filing History:

goldMedal10 out of 3,737 
 
Bristol-Myers Squibb Compnay
 patents
silverMedal1 out of 8 
 
Viiv Healthcare UK (No. 4) Limited
 patents

Years Active: 2010-2022

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 11369624 - Salts of prodrugs of piperazine and substituted piperidine antiviral agents (2022-06-28),
2. 11254679 - Process for the preparation of N-((1R,2S,5R)-5-(-butylamino)-2-((S)-3-(7--butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrroldin-1-yl)cyclohexyl)acetamide (2022-02-22),
3. 9718845 - Process for the preparation of cycloheptapyridine CGRP receptor antagonists (2017-08-01),
4. 8871771 - Salts of prodrugs of piperazine and substituted piperidine antiviral agents (2014-10-28),
5. 8669368 - Process for the preparation of cycloheptapyridine CGRP receptor antagonists (2014-03-11),
6. 8461333 - Salts of prodrugs of piperazine and substituted piperidine antiviral agents (2013-06-11),
7. 8168615 - Prodrugs of piperazine and substituted piperidine antiviral agents (2012-05-01),
8. 8143403 - CGRP receptor antagonists (2012-03-27),
9. 7745625 - Prodrugs of piperazine and substituted piperidine antiviral agents (2010-06-29),
10. 7723338 - [object Object] (2010-05-25),
11. 7671199 - Process for the preparation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-F][1,2,4]triazin-6-yloxy]-1-methylethyl ester (2010-03-02),

Title: The Inventor Spotlight: David Kenneth Leahy

Introduction:

David Kenneth Leahy, a prolific inventor hailing from Hightstown, NJ, boasts an impressive portfolio of 11 patents. With a focus on groundbreaking advancements in antiviral agents, his latest patents showcase his innovative spirit and commitment to improving healthcare.

Latest Patents:

One of Leahy's recent inventions includes the development of salts of prodrugs of piperazine and substituted piperidine antiviral agents. These compounds demonstrate potential in treating HIV infection, opening new avenues in the field of antiviral therapies. Additionally, he has introduced a novel process for the preparation of N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, showcasing his expertise in pharmaceutical synthesis.

Career Highlights:

Leahy has left a significant mark in the pharmaceutical industry, with notable stints at Bristol-Myers Squibb Company. His contributions to drug development and process improvement have earned him recognition among his peers and the scientific community at large.

Collaborations:

Throughout his career, Leahy has collaborated with esteemed professionals such as Chung-Pin H Chen and Yasutsugu Ueda. These collaborations have led to the exchange of ideas, fostering innovation and driving progress in the pharmaceutical field.

Conclusion:

In conclusion, David Kenneth Leahy's dedication to innovation and his remarkable contributions to the realm of antiviral agents underscore his status as a visionary inventor. His patented inventions stand as a testament to his ingenuity and commitment to advancing healthcare solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…